Search
(1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE
go.drugbank.com/drugs/DB07072ExperimentalSynonyms: (1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE(9S,12S)-9-(1-methylethyl)-7,10-dioxo-2-oxa-8,11-diazabicyclo[12.2.2]octadeca-1(16),14,17-triene-12-carboxylic acid
go.drugbank.com/drugs/DB07679ExperimentalSynonyms: (9S,12S)-9-(1-methylethyl)-7,10-dioxo-2-oxa-8,11-diazabicyclo[12.2.2]octadeca-1(16),14,17-triene-12-carboxylic acidAtuliflapon
go.drugbank.com/drugs/DB19029InvestigationalAtuliflapon is under investigation in clinical trial NCT05251259 (Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-severe Uncontrolled Asthma).
Synonyms: (1r,2r)-2-(4-(3-methyl-1h-pyrazol-5-yl)benzoyl)-n-(4-oxo-6,7-dihydro-5h-pyrazolo(1,5-a)pyrazine-3-yl)cyclohexanecarboxamide, Cyclohexanecarboxamide, 2-(4-(5-methyl-1h-pyrazol-3-yl)benzoyl)-n-(4,5,6,7-tetrahydro-4-oxopyrazolo(1,5-a)pyrazin-3-yl)-, (1r,2r)-Categories: Heterocyclic Compounds, 1-RingLuvixasertib
go.drugbank.com/drugs/DB19200InvestigationalLuvixasertib is under investigation in clinical trial NCT05251714 (CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer).
Categories: Heterocyclic Compounds, 1-RingSynonyms: Benzamide, n-cyclopropyl-4-(7-(((cis-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(3-pyridinyloxy)pyrazolo(1,5-a)pyrimidin-3-yl)-2-methyl-, N-cyclopropyl-4-(7-(((cis-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(3-pyridinyloxy)pyrazolo(1,5-a)pyrimidin-3-yl)-2-methylbenzamidePhenylacetylglutamine
go.drugbank.com/drugs/DB17167ExperimentalSynonyms: Antineoplaston as 2-1 component phenylacetylglutamine, L-glutamine, n2-(phenylacetyl)-TRK-001
go.drugbank.com/drugs/DB18577InvestigationalTRK-001 is an autologous regulatory T-cell therapy. It is being investigated for the prevention of graft rejection following solid organ transplantation.
Synonyms: Natural Regulatory T Cells (T-Regs), Expanded with Interleukin-2, ExpAct Beads (CD3/CD28; Miltenyi), Rapamycin and Transforming Growth Factor-betaC-(1-hydrogyl-beta-D-glucopyranosyl) formamide
go.drugbank.com/drugs/DB02719ExperimentalSynonyms: (2R,3R,4S,5S,6R)-2,3,4,5-Tetrahydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-carboxamide, C-(1-hydrogyl-beta-D-glucopyranosyl) formamidePiceatannol
go.drugbank.com/drugs/DB08399ExperimentalSynonyms: 4-[(E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,2-diol, 3-hydroxyresveratolPaclitaxel docosahexaenoic acid
go.drugbank.com/drugs/DB05297InvestigationalA combination of [docosahexaenoic Acid] (a natural fatty acid) and [paclitaxel] (an anticancer drug) being studied in the treatment of cancer. It is a type of mitotic inhibitor.
Synonyms: Paclitaxel 2'-(all-cis-4,7,10,13,16,19-docosahexaenoate)Nemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigationalNemolizumab is a humanized monoclonal modified immunoglobulin 2 (IgG2) antibody directed against interleukin-31 receptor alpha (IL-31RA),[L51159] which is an endogenous cytokine implicated in the pathophysiology … [L51159] Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis.
Synonyms: immunoglobulin G2-kappa, anti-[Homo sapiens IL31RA (interleukin 31 receptor subunit alpha)], humanized monoclonal antibody gamma2 heavy chain (1-445) [humanized VH (Homo sapiens IGHV1-2*02 (83.70%) -(IGHD, )-IGHJ5*01) [8.8.14] (1-121) -Homo sapiens IGHG2*0